KROS — Keros Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $594.96m
- $35.03m
- $3.55m
- 54
- 16
- 13
- 16
Annual cashflow statement for Keros Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -45.4 | -58.7 | -105 | -153 | -187 |
| Depreciation | |||||
| Non-Cash Items | 5.91 | 12.3 | 19.6 | 30.3 | 36.7 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 2.27 | -16.1 | 14.3 | -2.65 | -11.4 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -36.9 | -62.1 | -70.1 | -125 | -161 |
| Capital Expenditures | -0.294 | -1.02 | -1.24 | -2.46 | -1.93 |
| Purchase of Fixed Assets | |||||
| Cash from Investing Activities | -0.294 | -1.02 | -1.24 | -2.46 | -1.93 |
| Financing Cash Flow Items | -3.2 | 0 | -0.087 | -0.094 | -0.454 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 296 | 28.6 | 120 | 179 | 392 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 259 | -34.6 | 49 | 52 | 229 |